ARTICLE | Company News
Pfizer sales and marketing update
September 5, 2016 7:00 AM UTC
The U.K.’s NICE issued final guidance recommending the use of Bosulif bosutinib from Pfizer to treat chronic, accelerated and blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous le...